<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="clpb-def" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">clpb-def</book-part-id>
      <title-group>
        <title>CLPB Deficiency</title>
        <alt-title alt-title-type="alt-title">Synonym: Caseinolytic Peptidase B Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wortmann</surname>
            <given-names>Saskia B</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Clinical Lead, Pediatric Metabolic Disorders<break/>Department of Pediatrics<break/>Salzburger Landeskliniken and Paracelsus Medical University<break/>Salzburg, Austria</aff>
          <email>s.wortmann-hagemann@salk.at</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wevers</surname>
            <given-names>Ron A</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Translational Metabolic Laboratory<break/>Department of Laboratory Medicine<break/>Radboud University Medical Center <break/>Nijmegen, The Netherlands</aff>
          <email>ron.wevers@radboudumc.nl</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>de Brouwer</surname>
            <given-names>Arjan PM</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Assistant Professor, Department of Human Genetics<break/>Radboud University Medical Center<break/>Nijmegen, The Netherlands</aff>
          <email>Arjan.deBrouwer@radboudumc.nl</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>22</day>
          <month>11</month>
          <year>2016</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="clcn7" document-type="chapter"><italic toggle="yes">CLCN7</italic>-Related Osteopetrosis</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="oi" document-type="chapter"><italic toggle="yes">COL1A1/2</italic>-Related Osteogenesis Imperfecta</related-object>
      <abstract id="clpb-def.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>CLPB (<italic toggle="yes">c</italic>aseino<italic toggle="yes">l</italic>ytic <italic toggle="yes">p</italic>eptidase <italic toggle="yes">B</italic>) deficiency is characterized by neurologic involvement and neutropenia, which range from severe to mild. To date, a total of 26 individuals from 16 families have been reported.</p>
          <list list-type="bullet">
            <list-item>
              <p>In severe CLPB deficiency, death usually occurs at a few months of age as a result of significant neonatal neurologic involvement (hyperekplexia or absence of voluntary movements, hypotonia or hypertonia, swallowing problems, respiratory insufficiency, and epilepsy) and severe neutropenia associated with life-threatening infections.</p>
            </list-item>
            <list-item>
              <p>In moderate CLPB deficiency neurologic abnormalities in infancy are comparable to but less severe than those observed in the severe phenotype (e.g., hypotonia and feeding problems) and in later childhood can include spasticity, a progressive movement disorder (ataxia, dystonia, and/or dyskinesia), epilepsy, and intellectual disability ranging from mild learning disability to limited development of all cognitive and motor functions. Neutropenia is variable, but not life threatening.</p>
            </list-item>
            <list-item>
              <p>In mild CLPB deficiency there is no neurologic involvement, intellect is normal, and neutropenia is mild and intermittent. Life expectancy is normal.</p>
            </list-item>
          </list>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of CLPB deficiency is established in a proband with one or more suggestive clinical and/or imaging findings and/or elevated urinary excretion of 3-methylglutaconic acid (3-MGA), and identification of biallelic pathogenic variants in <italic toggle="yes">CLPB</italic> on molecular genetic testing.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Treatment is largely supportive. A multidisciplinary team including a metabolic physician, pediatric neurologist, developmental pediatrician, dietitian, physical therapist, and rehabilitation specialist is recommended. No specific dietary or metabolic treatment is available. Thorough developmental assessment is indicated for all children with cognitive difficulties to tailor special education services. Early intervention may include physical therapy, occupational therapy, and/or speech therapy. Treatment of the neurologic manifestations is per current clinical practice based on the findings. Granulocyte-colony stimulating factor (G-CSF) can be used to increase neutrophil counts to reduce the frequency of infections, especially in individuals with the mild or moderate phenotype.</p>
          <p><italic toggle="yes">Surveillance:</italic> Neurologic, ophthalmologic, immunologic/hematologic, and orthopedic evaluations are based on individual findings as needed.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Drugs potentially toxic to mitochondria, including chloramphenicol, aminoglycosides, linezolide, valproic acid, and nucleoside reverse transcriptase inhibitors.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>CLPB deficiency is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the <italic toggle="yes">CLPB</italic> pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives, prenatal testing for pregnancies at increased risk, and preimplantation genetic diagnosis are possible.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="clpb-def.Diagnosis">
        <title>Diagnosis</title>
        <sec id="clpb-def.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>CLPB (caseinolytic peptidase B) deficiency <bold>should be suspected</bold> in individuals with the following clinical, laboratory, and imaging findings.</p>
          <p><bold>Clinical findings.</bold> The disease spectrum of CLPB deficiency ranges from severe to mild. Findings by phenotype:</p>
          <list list-type="bullet">
            <list-item>
              <p>All phenotypes. Congenital or infantile cataracts</p>
            </list-item>
            <list-item>
              <p>Severe phenotype</p>
              <list list-type="bullet">
                <list-item>
                  <p>Neonates. Hyperekplexia, absence of voluntary movements, respiratory insufficiency, and swallowing problems</p>
                </list-item>
                <list-item>
                  <p>Neonates or infants. Microcephaly</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Moderate and severe phenotypes</p>
              <list list-type="bullet">
                <list-item>
                  <p>Infants. Ataxia, tremor and dystonia, dyskinesia</p>
                </list-item>
                <list-item>
                  <p>After infancy. Intellectual ability which can range from normal to severe intellectual disability (with virtually no development), and muscular hypotonia which can progress to spasticity</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>
            <bold>Laboratory findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Neutropenia beginning at birth can be chronic or intermittent (especially during infections) with absolute neutrophil count (ANC) ranging from severe to mild:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Severe. ANC &#x0003c;0.5 per mm<sup>3</sup></p>
                </list-item>
                <list-item>
                  <p>Moderate. ANC &#x0003c;1.0 per mm<sup>3</sup></p>
                </list-item>
                <list-item>
                  <p>Mild. ANC &#x0003c;1.5 per mm<sup>3</sup></p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Elevated urinary excretion of 3-methylglutaconic acid (3-MGA) (typically 2-10x the reference range) has been observed in all affected individuals to date.</p>
              <p>Note: (1) Each laboratory has its own reference range; for example, in the authors&#x02019; laboratory, normal is &#x0003c;20 mmol/mol creatinine. (2) The value can vary between samples from the same individual.</p>
            </list-item>
          </list>
          <p><bold>Imaging findings.</bold> Initial brain MRI is often unremarkable; however, during infancy progressive cerebral and cerebellar atrophy are seen on follow-up MRI in the majority of affected individuals [<xref ref-type="bibr" rid="clpb-def.REF.wortmann.2015.245">Wortmann et al 2015</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320260/">full text</ext-link>).</p>
        </sec>
        <sec id="clpb-def.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of CLPB deficiency <bold>is established</bold> in a proband with:</p>
          <list list-type="bullet">
            <list-item>
              <p>One or more suggestive clinical and/or imaging findings;</p>
              <p>AND/OR</p>
            </list-item>
            <list-item>
              <p>Elevated urinary excretion of 3-methylglutaconic acid (3-MGA);</p>
              <p>AND</p>
            </list-item>
            <list-item>
              <p>Identification of biallelic pathogenic variants in <italic toggle="yes">CLPB</italic> on molecular genetic testing (see <xref ref-type="table" rid="clpb-def.T.molecular_genetic_testing_use">Table 1</xref>).</p>
            </list-item>
          </list>
          <p>Molecular genetic testing approaches can include a combination of <bold>gene-targeted testing</bold> (multi-gene panel or single-gene testing) and <bold>genomic testing</bold> (comprehensive genomic sequencing) depending on the phenotype.</p>
          <p>Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing may not. Because the phenotype of CLPB deficiency is broad, children with the distinctive findings described in <xref ref-type="sec" rid="clpb-def.Suggestive_Findings">Suggestive Findings</xref> are likely to be diagnosed using gene-targeted testing (see <xref ref-type="sec" rid="clpb-def.Option_1">Option 1</xref>), whereas those with a mild phenotype indistinguishable from many other inherited disorders with intellectual disability and neurologic findings or neutropenia are more likely to be diagnosed using genomic testing (see <xref ref-type="sec" rid="clpb-def.Option_2">Option 2</xref>).</p>
          <sec id="clpb-def.Option_1">
            <title>Option 1</title>
            <p>When the phenotypic and laboratory findings suggest the diagnosis of CLPB deficiency, molecular genetic testing approaches can include <bold>single-gene testing</bold> and use of a <bold>multi-gene panel</bold>.</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">CLPB</italic> is performed first. If only one pathogenic variant is found, gene-targeted deletion/duplication analysis could be considered; however, to date no exon or whole gene deletions have been reported.</p>
              </list-item>
              <list-item>
                <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">CLPB</italic> and other genes of interest (see <xref ref-type="sec" rid="clpb-def.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of condition at the most reasonable cost while limiting secondary findings. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
              </list-item>
            </list>
          </sec>
          <sec id="clpb-def.Option_2">
            <title>Option 2</title>
            <p>When the phenotype is indistinguishable from many other inherited disorders with intellectual disability and neurologic findings or neutropenia, molecular genetic testing approaches can include <bold>genomic testing</bold> (comprehensive genomic sequencing; recommended) and/or <bold>gene-targeted testing</bold> (multi-gene panel; to consider).</p>
            <p><bold>Recommended testing.</bold> Comprehensive genomic sequencing (when available) including whole-exome sequencing (WES) and whole-genome sequencing (WGS) may be considered if the phenotype alone is insufficient to support gene-targeted testing. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            <p><bold>Testing to consider.</bold> A multi-gene panel that includes <italic toggle="yes">CLPB</italic> and other genes of interest (see <xref ref-type="sec" rid="clpb-def.Differential_Diagnosis">Differential Diagnosis</xref>) may be considered; however, given the rarity of CLPB deficiency many multi-gene panels for intellectual disability and/or this complex neurologic phenotype or neutropenia may not include this gene.</p>
            <table-wrap id="clpb-def.T.molecular_genetic_testing_use" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Molecular Genetic Testing Used in CLPB Deficiency</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_clpb-def.T.molecular_genetic_testing_use_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_clpb-def.T.molecular_genetic_testing_use_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_clpb-def.T.molecular_genetic_testing_use_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_clpb-def.T.molecular_genetic_testing_use_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">CLPB</italic>
                    </td>
                    <td headers="hd_h_clpb-def.T.molecular_genetic_testing_use_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_clpb-def.T.molecular_genetic_testing_use_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">16/16&#x000a0;<sup>4</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_clpb-def.T.molecular_genetic_testing_use_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_clpb-def.T.molecular_genetic_testing_use_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="clpb-def.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="clpb-def" object-id="clpb-def.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="clpb-def.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="clpb-def.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
                </fn>
                <fn id="clpb-def.TF.1.3">
                  <label>3. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="clpb-def.TF.1.4">
                  <label>4. </label>
                  <p><xref ref-type="bibr" rid="clpb-def.REF.capochichi.2015.303">Capo-Chichi et al [2015]</xref>, <xref ref-type="bibr" rid="clpb-def.REF.kanabus.2015.211">Kanabus et al [2015]</xref>, <xref ref-type="bibr" rid="clpb-def.REF.saunders.2015.258">Saunders et al [2015]</xref>, <xref ref-type="bibr" rid="clpb-def.REF.wortmann.2015.245">Wortmann et al [2015]</xref>, <xref ref-type="bibr" rid="clpb-def.REF.kiykim.2016.1">Kiykim et al [2016]</xref></p>
                </fn>
                <fn id="clpb-def.TF.1.5">
                  <label>5. </label>
                  <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
                </fn>
                <fn id="clpb-def.TF.1.6">
                  <label>6. </label>
                  <p>No deletions or duplications involving <italic toggle="yes">CLPB</italic> have been reported.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
      </sec>
      <sec id="clpb-def.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="clpb-def.Clinical_Description">
          <title>Clinical Description</title>
          <p>The disease spectrum of CLPB deficiency ranges from severe to moderate to mild as determined by neurologic involvement and neutropenia. Children with neonatal onset or early-infantile onset have severe involvement and may die from complications of their disease, whereas those with late-infantile and early-childhood onset have a milder clinical presentation [Wortmann et al, unpublished data].</p>
          <p>While many, but not all, individuals with CLPB deficiency have bilateral congenital or infantile cataracts, their presence is not associated with the severity of the neurologic involvement or neutropenia.</p>
          <p>Although no typical dysmorphic features have been reported, secondary dysmorphic features due to muscle involvement and movement disorder can be seen.</p>
          <p>To date a total of 26 individuals from 16 families with CLPB deficiency have been reported in the literature (n=14 [<xref ref-type="bibr" rid="clpb-def.REF.wortmann.2015.245">Wortmann et al 2015</xref>], n=5 [<xref ref-type="bibr" rid="clpb-def.REF.saunders.2015.258">Saunders et al 2015</xref>], n=4 [<xref ref-type="bibr" rid="clpb-def.REF.capochichi.2015.303">Capo-Chichi et al 2015</xref>], n=2 [<xref ref-type="bibr" rid="clpb-def.REF.kanabus.2015.211">Kanabus et al 2015</xref>] and n=1 [<xref ref-type="bibr" rid="clpb-def.REF.kiykim.2016.1">Kiykim et al 2016</xref>]). Most have been identified as neonates; all were symptomatic by early childhood.</p>
          <sec id="clpb-def.Severe_Phenotype">
            <title>Severe Phenotype</title>
            <p><bold>Neurologic.</bold> Affected infants come to attention at birth with significant neurologic involvement that can include hyperekplexia or absence of voluntary movements, hypotonia or hypertonia, swallowing problems, respiratory insufficiency, microcephaly (15/23 individuals) and epileptic seizures (with a burst suppression pattern on EEG). All affected infants require neonatal intensive care.</p>
            <p>These infants show no motor or intellectual development, and generally die in the first months of life.</p>
            <p>Retrospectively, many mothers of infants with the severe phenotype reported issues during the pregnancy, including decreased or increased fetal movements and intrauterine growth restriction [Wortmann et al, unpublished data].</p>
            <p><bold>Neutropenia.</bold> All infants with the severe phenotype had chronic, severe congenital neutropenia (ANC &#x0003c;500 per mm<sup>3</sup>) associated with life-threatening infections. Several affected infants progressed to a myelodysplastic syndrome/leukemia-like condition within the first months of life.</p>
          </sec>
          <sec id="clpb-def.Moderate_Phenotype">
            <title>Moderate Phenotype</title>
            <p><bold>Neurologic.</bold> The neonatal course is often complicated by adaptive problems in the broadest sense as well as neurologic abnormalities that are comparable to but less severe than those observed in the severe phenotype (e.g., hypotonia and feeding problems).</p>
            <p>Subsequent neurologic involvement varies. In many with neonatal onset generalized hypotonia progresses during childhood to spasticity (mainly of the legs). Many have an infantile-onset progressive movement disorder that can include ataxia, dystonia, or dyskinesia of varying severity. Several have epileptic seizures. All but two have intellectual disability that ranges from mild learning disability to very limited development of all cognitive and motor functions.</p>
            <p><bold>Neutropenia</bold> with varying ANC is common. Some affected individuals are only neutropenic during infections and some have recurrent (although not life-threatening) infections, including in the neonatal period.</p>
            <p><bold>Other.</bold> Many show biochemical evidence of endocrine abnormalities (e.g., hypothyroidism).</p>
          </sec>
          <sec id="clpb-def.Mild_Phenotype">
            <title>Mild Phenotype</title>
            <p>Mildly affected individuals show only some clinical signs and symptoms without progression and survive without significant disease burden into adulthood.</p>
            <p><bold>Neurologic.</bold> There is no neurologic involvement; intellect is normal.</p>
            <p><bold>Neutropenia</bold> is mild and intermittent without increased risk of infection.</p>
            <p><bold>Other findings.</bold> Nephrocalcinosis and renal cysts without associated medical complications have been described in two individuals with the mild phenotype [<xref ref-type="bibr" rid="clpb-def.REF.kanabus.2015.211">Kanabus et al 2015</xref>].</p>
          </sec>
        </sec>
        <sec id="clpb-def.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>The study of genotype-phenotype correlations is hampered by the small number of individuals with CLPB deficiency. The number of patients sharing the same genotype is low.</p>
          <p>An overview of all reported affected individuals revealed preliminary evidence in support of a genotype-phenotype correlation: individuals with the most severe phenotypes often have pathogenic variants predicted to lead to the complete absence of functional protein.</p>
        </sec>
        <sec id="clpb-def.Nomenclature">
          <title>Nomenclature</title>
          <p>CLPB deficiency may also be referred to as CLPB defect [<xref ref-type="bibr" rid="clpb-def.REF.wortmann.2013a.923">Wortmann et al 2013a</xref>, <xref ref-type="bibr" rid="clpb-def.REF.capochichi.2015.303">Capo-Chichi et al 2015</xref>, <xref ref-type="bibr" rid="clpb-def.REF.kanabus.2015.211">Kanabus et al 2015</xref>, <xref ref-type="bibr" rid="clpb-def.REF.saunders.2015.258">Saunders et al 2015</xref>, <xref ref-type="bibr" rid="clpb-def.REF.wortmann.2015.245">Wortmann et al 2015</xref>].</p>
          <p>In <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/616271">OMIM</ext-link>, CLPB deficiency is referred to as 3-methylglutaconic aciduria with cataracts, neurologic involvement and neutropenia (MEGCANN).</p>
        </sec>
        <sec id="clpb-def.Prevalence">
          <title>Prevalence</title>
          <p>CLPB deficiency is rare. A total of 26 individuals with CLPB deficiency have been reported to date (n= 14 [<xref ref-type="bibr" rid="clpb-def.REF.wortmann.2015.245">Wortmann et al 2015</xref>], n=5 [<xref ref-type="bibr" rid="clpb-def.REF.saunders.2015.258">Saunders et al 2015</xref>], n=4 [<xref ref-type="bibr" rid="clpb-def.REF.capochichi.2015.303">Capo-Chichi et al 2015</xref>], n=2 [<xref ref-type="bibr" rid="clpb-def.REF.kanabus.2015.211">Kanabus et al 2015</xref>], n=1 [<xref ref-type="bibr" rid="clpb-def.REF.kiykim.2016.1">Kiykim et al 2016</xref>]). The affected individuals reported are of European, North American, and Asian ancestry.</p>
          <p>In the largely Inuit population of Greenland the carrier frequency of the <xref ref-type="table" rid="clpb-def.T.selected_clpb_pathogenic_vari">c.803C&#x0003e;T</xref> variant was determined to be 3.3%, which is comparable to carrier frequencies of other founder variants in Greenland.</p>
        </sec>
      </sec>
      <sec id="clpb-def.Genetically_Related_Allelic_Dis">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with biallelic pathogenic variants in <italic toggle="yes">CLPB</italic>.</p>
      </sec>
      <sec id="clpb-def.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Table 2. Disorders to Consider in the Differential Diagnosis of CLPB Deficiency</p>
        <table-wrap id="clpb-def.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_clpb-def.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Discriminative Feature</th>
                <th id="hd_h_clpb-def.Tc_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Disorder</th>
                <th id="hd_h_clpb-def.Tc_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene(s)</th>
                <th id="hd_h_clpb-def.Tc_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">MOI</th>
                <th id="hd_h_clpb-def.Tc_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Additional Hallmarks&#x000a0;<sup>1</sup> of the Phenotype</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_clpb-def.Tc_1_1_1_1" rowspan="8" valign="middle" align="left" scope="row" colspan="1">3-MGA-uria&#x000a0;<sup>2</sup></td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">TAZ defect (<related-object link-type="booklink" source-id="gene" document-id="barth" document-type="chapter">Barth syndrome</related-object>)</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">TAZ</italic>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">XL</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">In affected males: growth delay in infancy, cardiomyopathy (left ventricular non-compaction), neutropenia, myopathy, typical facial features, hypocholesterolemia, &#x00026; a cognitive phenotype</td>
              </tr>
              <tr>
                <td headers="hd_h_clpb-def.Tc_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">OPA3 defect (Costeff syndrome; <related-object link-type="booklink" source-id="gene" document-id="mga3" document-type="chapter"><italic toggle="yes">OPA3</italic>-related 3-methylglutaconic aciduria</related-object>)</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">OPA3</italic>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">In infants: optic atrophy &#x00026; movement disorder (ataxia or extrapyramidal disorder)</td>
              </tr>
              <tr>
                <td headers="hd_h_clpb-def.Tc_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">SERAC1 defect (<related-object link-type="booklink" source-id="gene" document-id="megdel" document-type="chapter">MEGDEL syndrome</related-object>)</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">SERAC1</italic>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Neonatal hypoglycemia &#x00026; liver failure&#x000a0;<sup>3</sup><break/>In the 2<sup>nd</sup> year of life: progressive SNHL &#x00026; neurologic manifestations (truncal hypotonia, spasticity of the limbs, dystonia, severe ID/DD, Leigh syndrome-like findings on MRI)</td>
              </tr>
              <tr>
                <td headers="hd_h_clpb-def.Tc_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">TMEM70 defect (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/614052">OMIM</ext-link>)</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">TMEM70</italic>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">To date no specific syndromic presentation<break/>Typically in neonates: hyperammonemia, lactic acidosis, muscular hypotonia, hypertrophic cardiomyopathy, psychomotor retardation<break/>In individuals surviving neonatal period: DD</td>
              </tr>
              <tr>
                <td headers="hd_h_clpb-def.Tc_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">DNAJC19 defect (DCMA syndrome) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/610198">OMIM</ext-link>)</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">DNAJC5</italic>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Characteristic combination of childhood-onset dilated cardiomyopathy, non-progressive cerebellar ataxia, testicular dysgenesis, growth failure</td>
              </tr>
              <tr>
                <td headers="hd_h_clpb-def.Tc_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">AUH defect (3-methylglutaconyl-CoA hydratase deficiency) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/250950">OMIM</ext-link>)</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">AUH</italic>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Adult-onset progressive spasticity &#x00026; dementia w/characteristic slowly developing radiologic picture of extensive leukoencephalopathy&#x000a0;<sup>4</sup><break/>Uniquely distinguished by elevated urinary excretion of 3-hydroxyisovaleric acid (3-HIVA)</td>
              </tr>
              <tr>
                <td headers="hd_h_clpb-def.Tc_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">AGK defect (Sengers syndrome) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/212350">OMIM</ext-link>)</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">AGK</italic>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Characteristic combination of bilateral cataracts, hypertrophic cardiomyopathy, &#x00026; no to mild ID<break/>Can be lethal in neonatal period but survivors to adulthood w/mild involvement are known</td>
              </tr>
              <tr>
                <td headers="hd_h_clpb-def.Tc_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Not otherwise specified 3-MGA-uria (former 3-MGCA 4)</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                <td headers="hd_h_clpb-def.Tc_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Normal 3-methylglutaconyl-CoA hydratase enzyme activity &#x00026; no defect in <italic toggle="yes">TAZ</italic>, <italic toggle="yes">OPA3</italic>, <italic toggle="yes">SERAC1,</italic>
<italic toggle="yes">TMEM70</italic>, <italic toggle="yes">DNAJC5</italic>, <italic toggle="yes">AUH</italic>, or <italic toggle="yes">AGK</italic></td>
              </tr>
              <tr>
                <td headers="hd_h_clpb-def.Tc_1_1_1_1" rowspan="5" valign="middle" align="left" scope="row" colspan="1">Congenital neutropenia &#x00026; cyclic neutropenia</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="cyclic-n" document-type="chapter"><italic toggle="yes">ELANE</italic>-related neutropenia</related-object>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">ELANE</italic>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AD</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Isolated neutropenia; no involvement of the CNS or other organs</td>
              </tr>
              <tr>
                <td headers="hd_h_clpb-def.Tc_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="g6pc3-def" document-type="chapter">G6PC3 deficiency</related-object>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">G6PC3</italic>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Presence of cardiovascular and/or urogenital abnormalities</td>
              </tr>
              <tr>
                <td headers="hd_h_clpb-def.Tc_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">X-linked congenital neutropenia (see <related-object link-type="booklink" source-id="gene" document-id="was" document-type="chapter"><italic toggle="yes">WAS</italic>-Related Disorders</related-object>)</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">WAS</italic>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">XL</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Isolated neutropenia; no involvement of the CNS or other organs</td>
              </tr>
              <tr>
                <td headers="hd_h_clpb-def.Tc_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="gata1" document-type="chapter"><italic toggle="yes">GATA1</italic>-related X-linked cytopenia</related-object>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">GATA1</italic>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">XL</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Typical presentation in affected males: bleeding disorder &#x00026; anemia; neutropenia occurs later</td>
              </tr>
              <tr>
                <td headers="hd_h_clpb-def.Tc_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="sds" document-type="chapter">Shwachman-Diamond syndrome</related-object>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">SBDS</italic>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AR</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Intestinal malabsorption due to exocrine pancreatic dysfunction</td>
              </tr>
              <tr>
                <td headers="hd_h_clpb-def.Tc_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Hyperekplexia</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                  <related-object link-type="booklink" source-id="gene" document-id="hyperek" document-type="chapter">Hereditary hyperekplexia</related-object>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                  <italic toggle="yes">ARHGEF9<break/>GLRA1<break/>GLRB<break/>GPHN<break/>SLC6A5</italic>
                </td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">AD<break/>AR<break/>XL</td>
                <td headers="hd_h_clpb-def.Tc_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Generalized stiffness immediately after birth normalizes in first years of life.<break/>Unexpected (particularly auditory) stimuli cause excessive startle reflex (eye blinking, flexor spasm of the trunk), followed by a short period of generalized stiffness during which voluntary movements are impossible.<break/>Neutropenia/severe infections, respiratory insufficiency, &#x00026; swallowing problems are not seen in neonates; affected individuals improve over time.</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>MOI = mode of inheritance</p>
            </fn>
            <fn>
              <p>AD = autosomal dominant</p>
            </fn>
            <fn>
              <p>AR = autosomal recessive</p>
            </fn>
            <fn>
              <p>XL = X-linked</p>
            </fn>
            <fn>
              <p>SNHL = sensorineural hearing loss</p>
            </fn>
            <fn>
              <p>ID = intellectual disability</p>
            </fn>
            <fn>
              <p>DD = developmental delay</p>
            </fn>
            <fn id="clpb-def.TF.c.1">
              <label>1. </label>
              <p>In addition to discriminative feature shown in column 1</p>
            </fn>
            <fn id="clpb-def.TF.c.2">
              <label>2. </label>
              <p>Increased urinary excretion of 3-MGA, known as 3-methylglutaconic aciduria (3-MGA-uria), is a relatively common finding in children investigated for suspected inborn errors of metabolism [<xref ref-type="bibr" rid="clpb-def.REF.wortmann.2013b.913">Wortmann et al 2013b</xref>]. The classification of inborn errors of metabolism with 3-MGA-uria as discriminative feature has recently been updated. Click <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="clpb-def-new_classification.pdf" content-type="local-data">here</inline-supplementary-material> (pdf) [<xref ref-type="bibr" rid="clpb-def.REF.wortmann.2013a.923">Wortmann et al 2013a</xref>].</p>
            </fn>
            <fn id="clpb-def.TF.c.3">
              <label>3. </label>
              <p>
                <xref ref-type="bibr" rid="clpb-def.REF.sarig.2013.2204">Sarig et al [2013]</xref>
              </p>
            </fn>
            <fn id="clpb-def.TF.c.4">
              <label>4. </label>
              <p>
                <xref ref-type="bibr" rid="clpb-def.REF.wortmann.2010.1079">Wortmann et al [2010]</xref>
              </p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>Click <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="clpb-def-new_classification.pdf" content-type="local-data">here</inline-supplementary-material> (pdf) for information on classification of inborn errors of metabolism in which 3-methylglutaconic aciduria is a discriminative feature.</p>
      </sec>
      <sec id="clpb-def.Management">
        <title>Management</title>
        <sec id="clpb-def.Evaluations_Following_Initial_D">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with CLPB deficiency, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Complete physical examination</p>
            </list-item>
            <list-item>
              <p>Complete neurologic examination, including brain MRI (if not performed at the time of diagnosis)</p>
            </list-item>
            <list-item>
              <p>Developmental assessment or IQ testing (depending on the age of the individual at the time of diagnosis)</p>
            </list-item>
            <list-item>
              <p>For those with significant neurologic problems:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Complete evaluation of feeding and diet to determine if tube feeding or gastrostomy is necessary</p>
                </list-item>
                <list-item>
                  <p>Evaluation of excessive drooling to determine if the risk of aspiration and/or dehydration is increased</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Complete ophthalmologic examination to evaluate for cataracts (if not performed at the time of diagnosis)</p>
            </list-item>
            <list-item>
              <p>Absolute neutrophil count (ANC) is recommended to determine the need for granulocyte-colony stimulating factor (G-CSF) treatment.</p>
            </list-item>
            <list-item>
              <p>Ultrasound examination of the kidneys for evidence of nephrocalcinosis or cysts</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="clpb-def.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Treatment is supportive. Care is best provided by a multidisciplinary team including a metabolic pediatrician, pediatric neurologist, dietitian, and physical therapist when possible.</p>
          <p>No specific dietary or other metabolic treatment is available.</p>
          <p>Thorough developmental assessment is indicated for all children who exhibit cognitive difficulties in order to determine strengths and weaknesses and to tailor special education services. Early intervention may include physical therapy, occupational therapy, and/or speech therapy.</p>
          <p>Treatment of the neurologic manifestations is per current clinical practice based on the findings. To date no specific recommendations regarding the use of antiepileptic drugs are available.</p>
          <p>Excessive drooling can be reduced with botulinum toxin injection in the salivary glands, extirpation of saliva glands, and/or re-routing of glandular ducts [SB Wortmann, personal communication].</p>
          <p>Granulocyte-colony stimulating factor (G-CSF) administered subcutaneously can be used to increase neutrophil counts to help reduce the frequency of infections, especially in individuals with the mild or moderate phenotype (see <xref ref-type="sec" rid="clpb-def.Clinical_Description">Clinical Description</xref>) [SB Wortmann, personal communication].</p>
          <p>Note: Immunizations are not contraindicated and all children should be immunized as per national standards.</p>
        </sec>
        <sec id="clpb-def.Surveillance">
          <title>Surveillance</title>
          <p>Neurologic, ophthalmologic, immunologic/hematologic, and orthopedic evaluations are based on individual findings as needed.</p>
        </sec>
        <sec id="clpb-def.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Drugs potentially toxic to mitochondria (including chloramphenicol, aminoglycosides, linezolide, valproic acid, and nucleoside reverse transcriptase inhibitors) should be avoided.</p>
        </sec>
        <sec id="clpb-def.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="clpb-def.Related_Genetic_Counseling_Issu">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="clpb-def.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="clpb-def.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="clpb-def.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>CLPB deficiency is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="clpb-def.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">CLPB</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with CLPB deficiency are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">CLPB</italic>.</p>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier of a <italic toggle="yes">CLPB</italic> pathogenic variant.</p>
        </sec>
        <sec id="clpb-def.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">CLPB</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="clpb-def.Related_Genetic_Counseling_Issu">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="clpb-def.Prenatal_Testing_and_Preimplant">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">CLPB</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for CLPB deficiency are possible.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="clpb-def.Resources">
        <title>Resources</title>
      </sec>
      <sec id="clpb-def.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="clpb-def.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p><bold>Gene structure.</bold> The canonic splice isoform of <italic toggle="yes">CLPB</italic>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&#x00026;db=Nucleotide&#x00026;term=NM_030813&#x00026;doptcmdl=GenBank&#x00026;tool=genome.ucsc.edu">NM_030813.5</ext-link>, consists of 17 exons. Three other isoforms (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&#x00026;db=Nucleotide&#x00026;term=NM_001258392&#x00026;doptcmdl=GenBank&#x00026;tool=genome.ucsc.edu">NM_001258392.2</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&#x00026;db=Nucleotide&#x00026;term=NM_001258392&#x00026;doptcmdl=GenBank&#x00026;tool=genome.ucsc.edu">NM_001258393.2</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&#x00026;db=Nucleotide&#x00026;term=NM_001258392&#x00026;doptcmdl=GenBank&#x00026;tool=genome.ucsc.edu">NM_001258394.</ext-link>1) result in a shorter open reading frame.</p>
          <p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&#x00026;db=Nucleotide&#x00026;term=NM_001258392&#x00026;doptcmdl=GenBank&#x00026;tool=genome.ucsc.edu">NM_001258394.</ext-link>1 has more exons than NM_030813.5 resulting in a longer transcript; however, the resulting protein is shorter and has a different N-terminus because an additional exon in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&#x00026;db=Nucleotide&#x00026;term=NM_030813&#x00026;doptcmdl=GenBank&#x00026;tool=genome.ucsc.edu">NM_030813.5</ext-link> (between exons 2 and 3) contains an alternate start codon. Until proven otherwise, molecular genetic testing should include all exons of all isoforms.</p>
          <p>
            <bold>Pathogenic variants</bold>
          </p>
          <table-wrap id="clpb-def.T.selected_clpb_pathogenic_vari" orientation="portrait" position="anchor">
            <label>Table 4. </label>
            <caption>
              <p>Selected <italic toggle="yes">CLPB</italic> Pathogenic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                  <th id="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.748C&#x0003e;T</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg250Ter&#x000a0;<sup>1</sup></td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_3" rowspan="20" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&#x00026;db=Nucleotide&#x00026;term=NM_030813&#x00026;doptcmdl=GenBank&#x00026;tool=genome.ucsc.edu">NM_030813.5</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.803C&#x0003e;T</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr268Met&#x000a0;<sup>2</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.805G&#x0003e;A</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala269Thr&#x000a0;<sup>3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.815A&#x0003e;G</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr272Cys&#x000a0;<sup>1,&#x000a0;3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.961A&#x0003e;T</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Lys321Ter&#x000a0;<sup>2</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1222A&#x0003e;G</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg408Gly&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1233G&#x0003e;A</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Met411Ile&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1249C&#x0003e;T</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg417Ter&#x000a0;<sup>1,&#x000a0;2</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1305_1307inv</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu435_Gly436delinsAspPro&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1456T&#x0003e;C</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys486Arg&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1501G&#x0003e;A</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu501Lys&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1685delT</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ile562ThrfsTer23&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1700A&#x0003e;G</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr567Cys&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1772C&#x0003e;T</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala591Val&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1850A&#x0003e;G</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr617Cys&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1882C&#x0003e;T</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg628Cys&#x000a0;<sup>5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1915G&#x0003e;A</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu639Lys&#x000a0;<sup>5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1937dupG</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys647LeufsTer26&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1937G&#x0003e;T</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly646Val&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2045T&#x0003e;A</td>
                  <td headers="hd_h_clpb-def.T.selected_clpb_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ile682Asn&#x000a0;<sup>1</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="clpb-def.TF.4.1">
                <label>1. </label>
                <p>
                  <xref ref-type="bibr" rid="clpb-def.REF.wortmann.2015.245">Wortmann et al [2015]</xref>
                </p>
              </fn>
              <fn id="clpb-def.TF.4.2">
                <label>2. </label>
                <p>
                  <xref ref-type="bibr" rid="clpb-def.REF.saunders.2015.258">Saunders et al [2015]</xref>
                </p>
              </fn>
              <fn id="clpb-def.TF.4.3">
                <label>3. </label>
                <p>
                  <xref ref-type="bibr" rid="clpb-def.REF.kiykim.2016.1">Kiykim et al [2016]</xref>
                </p>
              </fn>
              <fn id="clpb-def.TF.4.4">
                <label>4. </label>
                <p>
                  <xref ref-type="bibr" rid="clpb-def.REF.capochichi.2015.303">Capo-Chichi et al [2015]</xref>
                </p>
              </fn>
              <fn id="clpb-def.TF.4.5">
                <label>5. </label>
                <p>
                  <xref ref-type="bibr" rid="clpb-def.REF.kanabus.2015.211">Kanabus et al [2015]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> CLPB is a mitochondrial protein of unknown function in human. The bacterial homologue functions as a chaperone facilitating the de- and proper re-folding of misfolded proteins.</p>
          <p>CLPB, a member of the large AAA (ATPases associated with diverse cellular activities) protein superfamily, consists of 707 amino acids and contains two main functional domains: the ankyrin domain implicated in a wide range of protein-protein interactions and the ATPase domain. Members of this superfamily are involved in various processes, such as DNA replication and repair and protein disaggregation and refolding, and operate as part of dynein motors, as chelatases or proteases [<xref ref-type="bibr" rid="clpb-def.REF.snider.2008.216">Snider et al 2008</xref>].</p>
          <p><bold>Abnormal gene product.</bold> Although the function of CLPB is unknown, loss of protein function results in CLPB deficiency.</p>
        </sec>
      </sec>
      <sec id="clpb-def.References">
        <title>References</title>
        <sec id="clpb-def.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="clpb-def.Literature_Cited.reflist0">
            <ref id="clpb-def.REF.capochichi.2015.303">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Capo-Chichi</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boissel</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brustein</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pickles</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fallet-Bianco</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nassif</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patry</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dobrzeniecka</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liao</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labuda</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Samuels</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamdan</surname>
                    <given-names>FF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vande Velde</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drapeau</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michaud</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <article-title>Disruption of CLPB is associated with congenital microcephaly, severe encephalopathy and 3-methylglutaconic aciduria.</article-title>
                <source>J Med Genet.</source>
                <year>2015</year>
                <volume>52</volume>
                <fpage>303</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">25650066</pub-id>
              </element-citation>
            </ref>
            <ref id="clpb-def.REF.kanabus.2015.211">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kanabus</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shahni</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saldanha</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plagnol</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoff</surname>
                    <given-names>WV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heales</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahman</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Bi-allelic CLPB mutations cause cataract, renal cysts, nephrocalcinosis and 3-methylglutaconic aciduria, a novel disorder of mitochondrial protein disaggregation.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2015</year>
                <volume>38</volume>
                <fpage>211</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">25595726</pub-id>
              </element-citation>
            </ref>
            <ref id="clpb-def.REF.kiykim.2016.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kiykim</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garncarz</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karakoc-Aydiner</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiykim</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yesil</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boztug</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baris</surname>
                    <given-names>S.</given-names>
                  </name>
                </person-group>
                <article-title>Novel CLPB mutation in a patient with 3-methylglutaconic aciduria causing severe neurological involvement and congenital neutropenia.</article-title>
                <source>Clin Immunol.</source>
                <year>2016</year>
                <volume>165</volume>
                <fpage>1</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">26916670</pub-id>
              </element-citation>
            </ref>
            <ref id="clpb-def.REF.sarig.2013.2204">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sarig</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldsher</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nousbeck</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuchs-Telem</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen-Katsenelson</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iancu</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manov</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sprecher</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Infantile mitochondrial hepatopathy is a cardinal feature of MEGDEL syndrome (3-methylglutaconic aciduria type IV with sensorineural deafness, encephalopathy and Leigh-like syndrome) caused by novel mutations in SERAC1.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2013</year>
                <volume>161A</volume>
                <fpage>2204</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">23918762</pub-id>
              </element-citation>
            </ref>
            <ref id="clpb-def.REF.saunders.2015.258">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Saunders</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wibrand</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ravn</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bross</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thiffault</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christensen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Atherton</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farrow</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kingsmore</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ostergaard</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>CLPB variants associated with autosomal-recessive mitochondrial disorder with cataract, neutropenia, epilepsy, and methylglutaconic aciduria.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2015</year>
                <volume>96</volume>
                <fpage>258</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">25597511</pub-id>
              </element-citation>
            </ref>
            <ref id="clpb-def.REF.snider.2008.216">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Snider</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thibault</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houry</surname>
                    <given-names>WA</given-names>
                  </name>
                </person-group>
                <article-title>The AAA+ superfamily of functionally diverse proteins.</article-title>
                <source>Genome Biol.</source>
                <year>2008</year>
                <volume>9</volume>
                <fpage>216</fpage>
                <pub-id pub-id-type="pmid">18466635</pub-id>
              </element-citation>
            </ref>
            <ref id="clpb-def.REF.wortmann.2013a.923">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wortmann</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anikster</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barth</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sperl</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zschocke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morava</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>Inborn errors of metabolism with 3-methylglutaconic aciduria as discriminative feature: proper classification and nomenclature.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2013a</year>
                <volume>36</volume>
                <fpage>923</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23296368</pub-id>
              </element-citation>
            </ref>
            <ref id="clpb-def.REF.wortmann.2013b.913">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wortmann</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kluijtmans</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodenburg</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sass</surname>
                    <given-names>JO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nouws</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Kaauwen</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleefstra</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tranebjaerg</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Vries</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isohanni</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walter</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alkuraya</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smuts</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reinecke</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Westhuizen</surname>
                    <given-names>FH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thorburn</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeitink</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morava</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>3-Methylglutaconic aciduria --lessons from 50 genes and 977 patients.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2013b</year>
                <volume>36</volume>
                <fpage>913</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">23355087</pub-id>
              </element-citation>
            </ref>
            <ref id="clpb-def.REF.wortmann.2010.1079">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wortmann</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kremer</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willemsen</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loupatty</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hogg</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Engelke</surname>
                    <given-names>UF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kluijtmans</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Illsinger</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcken</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cruysberg</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Das</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morava</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>3-Methylglutaconic aciduria type I redefined: a syndrome with late-onset leukoencephalopathy.</article-title>
                <source>Neurology.</source>
                <year>2010</year>
                <volume>75</volume>
                <fpage>1079</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">20855850</pub-id>
              </element-citation>
            </ref>
            <ref id="clpb-def.REF.wortmann.2015.245">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wortmann</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zi&#x00119;tkiewicz</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kousi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szklarczyk</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haack</surname>
                    <given-names>TB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gersting</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntau</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rakovic</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renkema</surname>
                    <given-names>GH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodenburg</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strom</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meitinger</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio-Gozalbo</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chrusciel</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Distelmaier</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Golzio</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jansen</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Karnebeek</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lillquist</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000fc;cke</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>&#x000d5;unap</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zordania</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaplito-Lee</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Bokhoven</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spelbrink</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaz</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pras-Raves</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ploski</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pronicka</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willemsen</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Brouwer</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prokisch</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katsanis</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>CLPB mutations cause 3-methylglutaconic aciduria, progressive brain atrophy, intellectual disability, congenital neutropenia, cataracts, movement disorder.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2015</year>
                <volume>96</volume>
                <fpage>245</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">25597510</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="clpb-def.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="clpb-def.Author_Notes">
          <title>Author Notes</title>
          <p>Dr SB Wortmann and Prof RA Wevers are interested in patients with elevated urinary excretion of 3-methylglutaconic acid. Combining the clinical, biochemical, and neuroradiologic findings of these patients they are able to define homogeneous subgroups. Next-generation sequencing is then used to identify the underlying genetic disorders in these subgroups, followed by biochemical investigations to characterize the function of the affected protein.</p>
        </sec>
        <sec id="clpb-def.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>22 November 2016 (bp) Review posted live</p>
            </list-item>
            <list-item>
              <p>21 June 2016 (sbw) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
